Skip to main content
    N

    Neuropace Inc (NPCE)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $8.20
    +0.23 (+2.89%)

    Market Cap: $260.45M

    Last updated: Nov 17, 2026 at 4:30 PM ET

    Neuropace Inc (NPCE) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Neuropace (NPCE) has a market cap of $260.45M and an enterprise value of $309.38M. It kept -20.00% of revenue as net income over the last 12 months. Its share count is up 3.66% from a year earlier.

    Total Valuation

    Enterprise value is 18.78% above the market cap, as debt exceeds cash.

    Market Cap$260.45M
    Enterprise Value$309.38M
    Latest price (Nov 17, 2026)$8.20

    Key Dates

    The next earnings report is expected on Mar 1, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 1, 2027 (expected)
    Last Earnings DateNov 12, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.71% in the quarter ended Sep 30, 2026 and grew 8.00% a year over 2 years.

    Shares Outstanding34.35M
    Shares Change (YoY)+3.66%
    Shares Change (QoQ)+0.71%
    Share Count Growth (2Y CAGR)+8.00%

    Valuation Ratios

    Sales and book value multiples are 3.0x and 24.5x. Its year-end P/S ranged from 0.2x to 5.5x from 2021 to 2025.

    P/S Ratio3.0x
    Forward P/S2.9x
    P/B Ratio24.5x

    Valuation history and multiples

    Price Statistics

    The stock is down 36.63% over 52 weeks and trades 36.63% below its 50-day average.

    Beta (1Y)1.35
    52-Week Change-36.63%
    1-Month Change-35.79%
    3-Month Change-43.99%
    6-Month Change-48.27%
    5-Year Change-18.87%
    Total Return (1Y)-36.63%
    Total Return (3Y CAGR)-1.76%
    Total Return (5Y CAGR)-6.45%
    Return vs SPY (1Y)-48.58%
    Max Drawdown (1Y)-60.81%
    Max Drawdown (3Y)-66.29%
    Sharpe Ratio (1Y)-0.67
    Correlation with SPY (1Y)0.27
    50-Day Average$12.94
    200-Day Average$14.69
    52-Week Range$5.46 to $19.60
    RSI (14 Days)26.5
    Average Volume (20 Days)535.05K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 5.26x current liabilities, and total debt is 5.15x shareholder equity.

    Current Ratio5.26x
    Quick Ratio4.09x
    Debt / Equity5.15x
    Interest Coverage-2.40x

    Returns and Efficiency

    Return on invested capital is -16.69% over the last 12 months, against a 5-year average of -17.06%.

    Return on Equity (ROE)-164.60%
    Return on Assets (ROA)-19.96%
    Return on Invested Capital (ROIC)-16.69%
    Return on Capital Employed (ROCE)-18.97%
    ROA (5Y Average)-29.58%
    ROIC (5Y Average)-17.06%
    Asset Turnover0.94x
    Inventory Turnover0.95x
    Receivables Turnover6.48x
    Cash Conversion Cycle362 days

    Scores

    NPCE has an Altman Z-Score of -5.03, in the distress zone below 1.81, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.

    Altman Z-Score-5.03
    Altman Z ZoneDistress
    Piotroski F-Score5 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $94.59M over the last 12 months is up 8.92% from the 12 months before.

    Revenue$94.59M
    Revenue Growth (YoY)+8.92%
    Gross Profit$77.00M
    Operating Income-$14.56M
    Pretax Income-$18.92M
    Net Income-$18.92M
    EBITDA-$12.54M
    EBIT-$14.93M
    Reported EPS (TTM)-$0.56

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 12.12% of the $94.78M in total assets.

    Cash and Equivalents$10.23M
    Total Debt$59.16M
    Net Debt$48.92M
    Net Debt Per Share$1.42
    Working Capital$68.47M
    Shareholder Equity$11.49M
    Book Value Per Share$0.33
    Total Assets$94.78M
    Total Liabilities$83.28M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $355.00K of capital spending, operating cash flow left -$12.41M of free cash flow.

    Operating Cash Flow-$12.06M
    Capital Expenditures$355.00K
    Free Cash Flow-$12.41M
    FCF Per Share-$0.36
    Depreciation and Amortization$2.39M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -15.39%, against a 5-year average of -45.43%.

    Gross Margin81.41%
    Operating Margin-15.39%
    Pretax Margin-20.00%
    Net Margin-20.00%
    EBITDA Margin-13.25%
    EBIT Margin-15.78%
    FCF Margin-13.13%
    Gross Margin (5Y Average)74.02%
    Operating Margin (5Y Average)-45.43%
    Net Margin (5Y Average)-57.82%

    Growth

    Revenue grew 29.99% a year over 3 years.

    Revenue Growth (3Y CAGR)+29.99%
    Revenue Growth (5Y CAGR)+19.44%
    Book Value Per Share Growth (2Y CAGR)-14.54%
    Tangible Book Per Share Growth (2Y CAGR)-14.54%

    Revenue and profit by year

    Dividends and Yields

    NPCE does not pay a dividend. Its free cash flow yield is -4.41%.

    FCF Yield-4.41%
    Buyback Yield-0.94%
    Shareholder Yield-0.94%

    Peer Position

    Against 12 similar companies, NPCE has the 5th highest P/S.

    P/S Ratio3.0x vs 1.6x median
    ROIC-16.69% vs -21.12% median
    Revenue Growth (Trailing 4 Quarters, YoY)+8.92% vs +14.10% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 5.56% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+5.56%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About NPCE

    What is NPCE's market cap?

    Neuropace has a market cap of $260.45M. Its enterprise value, which adds debt and subtracts cash, is $309.38M.

    How many shares of NPCE are outstanding?

    Neuropace has 34.35M shares outstanding. The count is up 3.66% from a year earlier.

    Does NPCE pay a dividend?

    No. Neuropace does not pay a dividend.

    How much debt does NPCE have?

    Neuropace has $59.16M of total debt and $10.23M of cash and equivalents, a net debt position of $48.92M.